Biotech Showcase 2019: Lipid Nanoparticle-Encased TUSC2 Gene Underpins Phase II NSCLC Asset
Julien Pham, President and COO of Genprex, describes to Mike Ward how the company is using a technology platform to wrap the TUSC2 gene in a cholesterol nanoparticle.
You may also be interested in...
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.